WELCOME TO The Biotechnology REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Questex LLC | November 20, 2018
Synthego has tapped Eurofins Genomics to distribute synthetic single guide RNA (sgRNA) products from its CRISPR evolution line of genome-editing kits. The partnership adds Eurofins customers in 44 countries to Synthego’s market, which, until now, was concentrated in the U.S. The Redwood City, California-based biotech aims to boost the cell and gene therapy space by making gene-editing tools more accessible to scientists around the world. The idea is to offer scientists the tools they need ...
Eurofins Discovery | November 04, 2020
Eurofins Discovery, the leading provider of services and products to the drug discovery industry, announced a new collaboration with Amphilix AG, a Swiss-based biotech company, to support a program aimed at identifying a treatment modulating key disease mechanisms. Amphilix AG will take advantage of Eurofins Discovery's DiscoveryOne™ offering, an integrated drug discovery platform providing expert support to progress programs to preclinical development and beyond. Amphilix will engage ...
Cell and Gene Therapy, MedTech
PRNewswire | June 30, 2023
Eurofins Genomics Blue Heron is thrilled to announce the launch of our cutting-edge IVT mRNA Synthesis Service. With this revolutionary service, we aim to offer a game-changing solution to the challenges of gene expression research.
The new service offers a comprehensive solution for researchers seeking high-quality, customizable mRNA synthesis with fast turnaround times. The IVT mRNA Synthesis Service is based on the latest in vitro transcription (IVT) technology, which allows ...
Labiotech.eu | January 28, 2020
A Swiss research group has developed tiny plastic particles that could carry gene therapies to the center of the cell with less risk of getting attacked by the immune system than conventional gene therapies. The majority of gene therapies in use today are delivered to the DNA of target cells using viral vectors. While efficient at their job, viral vectors can risk triggering the immune system to destroy them. This can lead to the therapy becoming ineffective....
Cell and Gene Therapy
MedTech, Industrial Impact
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE